Vir Biotechnology officer proposes $26.7K share sale

Vir Biotechnology's reported shares-outstanding figure is 169,215,958.

Available on EDGAR 11/03/2026 - 10:16 AM EST Accepted by SEC EDGAR 11/03/2026 - 10:15 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology, Inc. officer Vanina A. Huard de Verneuil reported a proposed sale of 2,407 common shares, with an approximate sale date of November 3, 2026, and an aggregate market value of $26,717.70. The listed broker is Fidelity Brokerage Services LLC. Huard de Verneuil also reported 1,343 common shares sold on November 2, 2026, for $15,221.96.

Key Figures

Common shares proposed for sale: 2,407 shares Aggregate market value: $26,717.70 Common shares sold: 1,343 shares +2 more

5 metrics

Common shares proposed for sale 2,407 shares Approximate sale date: November 3, 2026

Aggregate market value $26,717.70 Proposed sale

Common shares sold 1,343 shares November 2, 2026; reported sales during the past three months

Aggregate value of shares sold $15,221.96 November 2, 2026

Shares outstanding 169,215,958 shares Vir Biotechnology

Key Terms

Restricted Stock Vesting, Rule 144, attorney-in-fact

3 terms

Restricted Stock Vesting technical

"Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

attorney-in-fact regulatory

"as attorney-in-fact for Vanina Huard de Verneuil"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VIR shares did Vanina Huard de Verneuil propose to sell?

Officer Vanina A. Huard de Verneuil reported a proposed sale of 2,407 Vir Biotechnology common shares, with an approximate sale date of November 3, 2026, and an aggregate market value of $26,717.70. Fidelity Brokerage Services LLC is listed as the broker.

How many VIR shares did Vanina Huard de Verneuil sell in the past three months?

Vanina A. Huard de Verneuil's reported sales during the past three months included 1,343 common shares on November 2, 2026, valued at $15,221.96.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002036234
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	de Verneuil Vanina
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2407	26717.70	169215958	11/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/01/2026	Restricted Stock Vesting	Issuer			2407	11/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Vanina A. Huard De Verneuil 1800 Owens Street Suite 900 San Francisco CA 94158	Common	11/02/2026	1343	15221.96

144: Remarks and Signature

Remarks
Date of Notice	11/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Vanina Huard de Verneuil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)